1ebenovaD,KuzelovaK,Fuchso,et al.Interferon-alpha suppresses proliferation of chronic myelogennous leukemia cells k562 by extending cell cycles-phase without inducing apoptosis[J].Blood cells Mol Dis,2004,32(1):262-269.
2Mahon Fx,Delbrel x,cony-Makhonl P,et al.Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon a[J].J Clin Oncol,2002,(20):214.
3Baccarani M,Rosti G,de VivoA,et al.A randomized study of interferon-α versus interferon-a and low dose arabinosyl cytosine in chronic myeloid leukemia[J].Blood,2002,(99):1527.
4ODWYER ME.MAVRO MJ.DRNKERBJ.Recent advance in the treatment of chronic myelogenous leukemia[J].Annb Rev Med,2002,(53):369-381.
9Sahara N.Takeshita A.et al.phenylarsine oxide(PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As203 by activating the mitochondrial pathway[J].Leuk Lymphoma,2004,(45):987-995.
4Deininger MWN, Vieira S, Mendiola R, et al. bcr-abl tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia[J]. Cancer Res, 2000, 60:2049 -2055.
5O' Dwyer M E, Mauro M J, Druker B J. Recent advancements in the treatment of chronic myelogenous leukemia[J]. Annu Rev Med, 2002,53:369-381.
6Porosnicu M, Nimmanapalli R, Nguyen D, et al. Co- treatment with As2O3 enhances selective cytotoxic effects of STI-571 against bcr-ablpositive acute leukemia cells[J]. Leukemia, 2001, 15:772-778.
7La Rosee P, Johnson K, O'Dwyer M E, et al. In vitro studies of the combination of imatinib mesylate (Gleevec)> and arsenic trioxide (Trisenox) in chronic myelogenous leukemia[J]. Exp Hematol, 2002,30:729 -737.
8Wadhwa J, Szydlo R M, Apperley J F, et al. Factors affecting duration of survival after onset of blastic trans-formation of chronic myeloid leukemia. Blood, 2002,99:2304-2309.
9Deininger M W, Golderman J M, Lydon N, et al. The tyrosine kinase inhibitor CGP571 48B selectively inhibits the growth of BCR-ABL positive cells. Blood, 1997,90:3691-3698.
10Champlin R, Khouri I, Shimoni A, et al. Harnessing graft versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation,an evolving strategy for adoptive immunotherapy. Br J Haematol, 2000, 111:18-29.
